Investigational Drug Information for HKI-357
✉ Email this page to a colleague
What is the drug development status for HKI-357?
HKI-357 is an investigational drug.
There have been 22 clinical trials for HKI-357.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 9th 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Puma Biotechnology, Inc., Wyeth is now a wholly owned subsidiary of Pfizer, and NSABP Foundation Inc.
Summary for HKI-357
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 78 |
| WIPO Patent Applications | 61 |
| Japanese Patent Applications | 29 |
| Clinical Trial Progress | Phase 3 (2009-07-09) |
| Vendors | 31 |
Recent Clinical Trials for HKI-357
| Title | Sponsor | Phase |
|---|---|---|
| HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | Puma Biotechnology, Inc. | Phase 2 |
| HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | Translational Breast Cancer Research Consortium | Phase 2 |
| HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | Dana-Farber Cancer Institute | Phase 2 |
Clinical Trial Summary for HKI-357
Top disease conditions for HKI-357
Top clinical trial sponsors for HKI-357
US Patents for HKI-357
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
